SMAD9 Gene: Function, Mutations, and Role in Pulmonary Arterial Hypertension

SMAD9 (SMAD family member 9) encodes a receptor-regulated SMAD (R-SMAD) that mediates signaling by bone morphogenetic proteins (BMPs). Upon BMP receptor activation, SMAD9 is phosphorylated and forms a complex with SMAD4, translocating to the nucleus to regulate transcription of target genes. It acts as a negative regulator of BMP signaling and is critical for vascular development, particularly in pulmonary endothelium. Loss-of-function mutations in SMAD9 are associated with hereditary pulmonary arterial hypertension (PAH).

Tissue Expression

Cell Line Expression

Hotspot Mutations

Mutation functional classification

• BMP signaling pathway (Reactome: R-HSA-201451)

• TGF-beta signaling pathway (KEGG: hsa04350)

• Signaling by BMP (Reactome: R-HSA-201451)

SMAD9 (also known as SMAD8) is a 467-amino acid protein containing an N-terminal MH1 domain and a C-terminal MH2 domain. It is a receptor-regulated SMAD that specifically transduces BMP signals. Phosphorylation at the C-terminal SSXS motif by BMP type I receptors enables heteromeric complex formation with SMAD4. SMAD9 is highly expressed in lung endothelium and plays a critical role in maintaining vascular integrity. Mutations in SMAD9 cause familial pulmonary arterial hypertension (PAH) by disrupting BMP signaling, leading to endothelial dysfunction and vascular remodeling.